Join to access to all OVN content. Join for Free
First person profile: Leslie Bernstein, PhD: An epidemiologist known for her groundbreaking discoveries about breast cancer, Dr. Bernstein continues to push the field forward
breast cancer Leslie Bernstein epidemiologist

First person profile: Leslie Bernstein, PhD: An epidemiologist known for her groundbreaking discoveries about breast cancer, Dr. Bernstein continues to push the field forward


Share This Article


Summary

  • Dr. Leslie Bernstein is a renowned researcher in breast cancer risk and prevention at City of Hope, California.
  • Her colleague, Dr. Jonine Bernstein, highlights her groundbreaking work and passion for research.
  • They have collaborated on the WECARE Study, focusing on genetic susceptibility and radiation treatment's effects on breast cancer risk.
  • Dr. Bernstein cofounded the California Teachers Study in 1995, which has yielded significant findings in cancer and other diseases.
  • Notable work includes the first research linking physical activity to reduced breast cancer risk and studies on low-dose aspirin's effects on breast cancer.
  • She emphasizes the need for smaller studies to understand mechanisms for preventive measures in breast cancer.
  • Dr. Bernstein's background includes a passion for math, driven by her father, and a supportive relationship with her husband, Saul Bernstein.
  • She completed her advanced education later in life, obtaining a master's and PhD in biostatistics.
  • Dr. Bernstein is also a grandmother of 11, actively involved in guiding her grandchildren.
  • She is praised for her humility and supportiveness in the professional community.

When Leslie Bernstein, PhD, joined the faculty of City of Hope at the age of 67, she told the institution's leaders that she would stay for no more than a decade. After all, she had just spent 25 years at the University of Southern California (USC) in Los Angeles, serving as a professor in the department of preventive medicine, the medical school dean for faculty affairs, and the university vice provost for medical affairs. However, some 13 years after her pronouncement—with a move across the country to be closer to her daughter in New Jersey thrown in—Dr. Bernstein continues to work with the center remotely, publishing research and mentoring younger colleagues. “I'm hoping to retire soon, but so far the answer has been, ‘We'd rather you stay on,’” she says.

Click for Source Download PDF version
breast cancer, Leslie Bernstein, epidemiologist

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
OVN Avatar Qiyou Wu, Zhiwei Lian, Xin Wang, Hanchao Cheng, Jing Sun, Hui Yu, Gong Zhang, Fan Wu, Jian Liu and Chuanben Chen

Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China

Article
Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study
OVN Avatar Min Jeong Kim, Hyo Jung Kim, Danbee Kang, Hee Kyung Ahn, Soo-Yong Shin, Juhee Cho, Yeon Hee Park,

Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN